Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831

Jenna Rossoff, Jing Chen, Todd Alonzo, Jim Wang, Richard Aplenc, Alan Gamis, Betsy Hirsch, Gordana Raca, Soheil Meshinchi, Anders Kolb, Sarah Tasian, Jessica Pollard, Matthew Kutny, Todd Cooper

Blood (2025) 146 (Supplement 1): 877.

https://doi.org/10.1182/blood-2025-877

Published: 2025

Journal Articles

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

Zachary Graff, Todd Alonzo, Robert Gerbing, Jim Wang, Jessica Pollard, Soheil Meshinchi, Alan Gamis, Richard Aplenc, Betsy Hirsch, Gordana Raca, Todd Cooper, Matthew Kutny

Blood (2025) 146 (Supplement 1): 872.

https://doi.org/10.1182/blood-2025-872

Published: 2025

Journal Articles

Germline predisposition in pediatric malignancies: Insights from a retrospective study at Dana-Farber Cancer Institute

Blood (2025) 146 (Supplement 1): 3213.

https://doi.org/10.1182/blood-2025-3213

Published: 2025

Journal Articles

Asciminib pediatric formulation shows a tolerable safety profile in pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP): Second interim analysis from the ASC4KIDS study

Jessica Pollard, Hiroyuki Shimada, Shruti Kapoor, Matthias Hoch, Vishal Dhamal, Nithya Agrawal, Christine Rosko, Ana Paula Cardoso, Masakatsu Yanagimachi, Ho Joon Im, Markus Metzler, Nobuko Hijiya

Blood (2025) 146 (Supplement 1): 7312.

https://doi.org/10.1182/blood-2025-7312

Published: 2025

Journal Articles

Analysis of 3346 patients from the combined Children's Oncology Group AML studies further characterizes RAM immunophenotype AML and reveals other associated phenotypes and genetic drivers.

Andrew Menssen, Jacqueline Cook, Todd Alonzo, Robert Gerbing, Maria Pardo, Fan-Chi Hsu, Loren Lott, Fangyan Dai, Amenech Ashango, Thanh Thanh Dinh, Todd Cooper, Jessica Pollard, Katherine Tarlock, Lisa Brodersen, Michael Loken, Soheil Meshinchi, Chad Hudson

Blood (2025) 146 (Supplement 1): 337.

https://doi.org/10.1182/blood-2025-337

Published: 2025

Journal Articles

CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study

Jatinder K Lamba, PhD, Lata Chauhan, PhD, Michael R. Loken, PhD, Jessica Pollard, MD, Yi-Cheng Wang, MS, Ries E Rhonda, Richard Aplenc, MD PhD, Betsy A. Hirsch, PhD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Irwin D. Bernstein, MD, Alan S. Gamis, MD MPH, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 2743.

https://doi.org/10.1182/blood.V128.22.2743.2743

Published: 2016

Journal Articles

Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group

Todd M Cooper, DO, Robert B. Gerbing, MA, Todd A. Alonzo, PhD, Jessica Pollard, MD, Lillian Sung, MD PhD FRCPC, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH

Blood (2016) 128 (22): 2794.

https://doi.org/10.1182/blood.V128.22.2794.2794

Published: 2016

Journal Articles

Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Katherine Tarlock, MD, Todd M Cooper, DO, Todd A. Alonzo, PhD, Robert Gerbing, BS, Jessica Pollard, MD, Richard Aplenc, MD PhD, E. Anders Kolb, MD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2016) 128 (22): 2846.

https://doi.org/10.1182/blood.V128.22.2846.2846

Published: 2016

Journal Articles

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

Erin M. Guest, MD, Betsy A. Hirsch, PhD, E. Anders Kolb, MD, Todd A. Alonzo, PhD, Robert Gerbing, BS, Richard Aplenc, MD PhD, Jessica Pollard, MD, Lillian Sung, MD PhD FRCPC, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH, Susana C. Raimondi, PhD

Blood (2016) 128 (22): 1211.

https://doi.org/10.1182/blood.V128.22.1211.1211

Published: 2016

Journal Articles

The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group

Richard Aplenc, MD PhD, Soheil Meshinchi, MD PhD, Lillian Sung, MD PhD FRCPC, Todd A. Alonzo, PhD, Jessica Pollard, MD, Robert Gerbing, BS, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Michael R. Loken, PhD, Laura Winter, PharmD, Samir B. Kahwash, John K Choi, MD, John E Levine, MD MS, E. Anders Kolb, MD, Alan S. Gamis, MD MPH

Blood (2016) 128 (22): 899.

https://doi.org/10.1182/blood.V128.22.899.899

Published: 2016

Journal Articles

Treatment of 11q23/ MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Jessica Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Lillian Sung, MD PhD, Richard Aplenc, MD PhD, Erin M. Guest, MD, Irwin D. Bernstein, MD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH

Blood (2015) 126 (23): 799.

https://doi.org/10.1182/blood.V126.23.799.799

Published: 2015

Journal Articles

Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Jessica Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Wang, MS, Jason Joaquin, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Lillian Sung, MD PhD, Richard Aplenc, MD PhD, Irwin D. Bernstein, MD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 800.

https://doi.org/10.1182/blood.V126.23.800.800

Published: 2015

Journal Articles

Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study

Jatinder K Lamba, PhD, Lata Chauhan, PhD, Richard Aplenc, MD PhD, Maggie Skrypek, MD, Jessica Pollard, MD, Todd A. Alonzo, PhD, Y-C Wang, Irwin D. Bernstein, MD, Alan S. Gamis, MD MPH, Soheil Meshinchi, MD PhD

Blood (2015) 126 (23): 1260.

https://doi.org/10.1182/blood.V126.23.1260.1260

Published: 2015

Journal Articles

Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML

Jessica Pollard, MD, Bill H Chang, MD, PhD, Todd Michael Cooper, Thomas Gross, MD, PhD, Sumit Gupta, MD, Phoenix A. Ho, MD, Suzanne M. McGoldrick, MD, Tanya C. Watt, MD, MSc, India Sisler, MD, Blythe Thomson, MD, Ann E Woolfrey, MD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 3969.

https://doi.org/10.1182/blood.V122.21.3969.3969

Published: 2013

Journal Articles

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Todd Michael Cooper, Sharyn D. Baker, PharmD, PhD, Jennifer Direnzo, Tanya M. Trippett, Lia Gore, MD, Aru Narendran, MD, PhD, Keith J. August, M.D., M.Sc., Michael J. Absalon, MD, PhD, Jessica Boklan, MD, Jessica Pollard, MD, Daniel Magoon, Edward Allan R. Sison, MD, Patrick Brown, MD

Blood (2013) 122 (21): 2680.

https://doi.org/10.1182/blood.V122.21.2680.2680

Published: 2013

Journal Articles

Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group

Jessica Pollard, MD, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Susana C Raimondi, PhD, Betsy Hirsch, PhD, Richard Aplenc, MD, Alan S. Gamis, MD, MPH, Michael R. Loken, PhD, Soheil Meshinchi, MD, PhD

Blood (2013) 122 (21): 491.

https://doi.org/10.1182/blood.V122.21.491.491

Published: 2013

Journal Articles

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing, Jessica Pollard, Derek L. Stirewalt, Craig Hurwitz, Nyla A. Heerema, Betsy Hirsch, Susana C. Raimondi, Beverly Lange, Janet L. Franklin, Jerald P. Radich, Soheil Meshinchi

Blood (2009) 113 (26): 6558–6566.

https://doi.org/10.1182/blood-2008-10-184747

Published: 2009

Includes: Supplemental data

Journal Articles

Prevalence and Prognostic Implications of CEBPα Mutations in Pediatric AML.

Phoenix A. Ho, Todd A. Alonzo, Robert B. Gerbing, Jessica Pollard, Derek L. Stirewalt, Nyla A. Heerema, Beverly Lange, Jerald Radich, Soheil Meshinchi

Blood (2007) 110 (11): 1441.

https://doi.org/10.1182/blood.V110.11.1441.1441

Published: 2007

Journal Articles

Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.

Jessica Pollard, Todd Alonzo, Robert Gerbing, Rong Zeng, Betsy Hirsch, Susana Raimondi, Nyla Heerema, William Woods, Beverly Lange, Craig Hurwitz, Robert Arceci, Jerald Radich, Irwin Bernstein, Michael Heinrich, Soheil Meshinchi

Blood (2007) 110 (11): 1442.

https://doi.org/10.1182/blood.V110.11.1442.1442

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Etoposide can be safely removed from induction chemotherapy without impacting survival for pediatric acute myeloid leukemia – a report from the Children's oncology group study AAML1831

Central nervous system disease status significantly impacts survival in pediatric acute myeloid leukemia: A report from Children's Oncology Group study AAML1831

Germline predisposition in pediatric malignancies: Insights from a retrospective study at Dana-Farber Cancer Institute

Asciminib pediatric formulation shows a tolerable safety profile in pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP): Second interim analysis from the ASC4KIDS study

Analysis of 3346 patients from the combined Children's Oncology Group AML studies further characterizes RAM immunophenotype AML and reveals other associated phenotypes and genetic drivers.

CD33 Splicing Polymorphism Is a Strong Predictor of Therapeutic Efficacy of Gemtuzumab Ozogamicin in De Novo AML: Report from COG-AAML0531 Study

Relapse Following Initial Remission and Subsequent Outcome for Children with Relapsed Acute Myeloid Leukemia on the AAML0531 Phase III Study of Gemtuzumab Ozogamicin: A Report from the Children's Oncology Group

Mutational Concordance from Diagnosis and Relapse in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Prognostic Significance of 11q23/ MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group

Treatment of 11q23/ MLL + AML with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Prevalence and Prognostic Significance of KIT Mutations in Pediatric Core Binding Factor AML Patients Treated with Gemtuzumab Ozogamicin: Results from the Randomized Phase III Children's Oncology Group Trial AAML0531

Genetic Variations in Calicheamicin Pathway Genes Are Predictors of Gemtuzumab Ozogamicin Response in AML Patients: Results from COG-AAML0531 Study

Sorafenib Treatment Following Hematopoietic Stem Cell Transplant In Pediatric FLT3/ITD+ AML

Chemosensitization and Mobilization Of AML/ALL/MDS With Plerixafor (AMD 3100), a CXCR4 Antagonist: A Phase I Study Of Plerixafor + Cytarabine and Etoposide In Pediatric Patients With Acute Leukemia and MDS

Negative Prognostic Impact Of High CD33 Expression Is Negated With The Use Of Gemtuzumab Ozogamicin: A Report From The Children’s Oncology Group

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group

Prevalence and Prognostic Implications of CEBPα Mutations in Pediatric AML.

Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only